News | Proton Therapy | June 14, 2019

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

Streamlined quality assurance process will allow Netherlands center to treat more patients per day

University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA

June 14, 2019 – IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and clinically implemented a novel automated treatment log-based patient quality assurance (QA) approach for proton therapy. This enables them to reduce the time needed for the in-beam measurement-based conventional patient QA.

With this new approach, the center is now able to streamline and reduce the QA time per patient, extract more clinically relevant information from the QA data and establish continuous quality control of the treatment throughout the course. Furthermore, this will allow them to reduce the time to continue treatment course with adapted plans, when needed, and make a step towards supporting online adaptive workflows.

This new automated patient QA approach combines several open source projects: CAPTAIN, an automatic workflow manager using web-technology; a DICOM picture archiving and communication system (PACS) database (Orthanc) providing an interface with the treatment planning system (TPS); computation routines from open-REGGUI and others, developed at UMCG; and a Monte Carlo proton dose engine (MCsquare).

CAPTAIN, open-REGGUI and MCsquare are open-source research tools supported by the openPath initiative, which is aimed at researchers, medical physicists and clinicians to accelerate research. It is the first time that a center has applied the extensive internal QA validation of UMCG to use the open source software platform in the clinic.

Prof. Stefan Both, head of physics at UMCG, commented, “Thanks to the support of IBA and the OpenPath platform, we managed to develop and implement an automated patient QA process that will allow us to considerably reduce the time to perform patient QA operations from about 45 minutes to 5 minutes. This means we have today the capacity to treat [an] additional 1 to 2 fractions per day, shorten [by] two days the time from simulation to treatment delivery and explore adaptive proton therapy protocols to maximize the clinical potential of the proton treatment beam.”

For more information: www.iba-worldwide.com

Related Content

Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020.

Case abstraction study period was from 10 March to 7 April 2020. Follow-up of abstracted cases was until 7 May 2020. Courtesy of Nature Medicine

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The characterization of COVID-19
Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

Stephen M. Hahn, M.D., Commissioner of Food and Drugs - Food and Drug Administration

News | Coronavirus (COVID-19) | June 23, 2020
June 23, 2020 — On June 23, 2020, ...
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...